BACKGROUND: Hakata antigen (Hakata) is a novel serum glycoprotein that consists of collagen- and fibrinogen-like domains, similar to ficolin/p35. Our research suggested that serum Hakata may be a target of a polysaccharide (PSA) produced by Aerococcus viridans. METHODS: A. viridans was incubated with human plasma and Hakata-depleted plasma to examine Hakata binding and growth inhibition of A. viridans through binding with PSA. RESULTS: When A. viridans was mixed with human acid citrate dextrose-one (ACD-A) plasma, it pulled down Hakata complexed with mannose-binding lectin (MBL)-associated serine proteases 1 and 2 (MASP-1 and MASP-2). This complex had the potential for C4 deposition. Serum Hakata circulates as Hakata-MASPs complex in the blood and is proteolytically active. By mixing A. viridans with human plasma, we prepared a Hakata-depleted plasma, deficient in Hakata-MASPs complex. This plasma failed to inhibit A. viridans growth plasma, but does not inhibit Staphylococcus aureus, Yersinia enterocolitica and Escherichia coli. However, a decrease of growth inhibition of A. viridans in Hakata-depleted plasma could be restored by adding a Hakata-MASPs complex preparation in a dose-dependent manner. On the other hand, the Hakata-MASPs complex exhibited strong binding to A. viridans, but not to S. aureus, Y. enterocolitica and E. coli. CONCLUSIONS: The serum concentration of Hakata is linked with growth inhibition of A. viridans upon binding of Hakata via PSA. Copyright 2002 Elsevier Science B.V.
BACKGROUND: Hakata antigen (Hakata) is a novel serum glycoprotein that consists of collagen- and fibrinogen-like domains, similar to ficolin/p35. Our research suggested that serum Hakata may be a target of a polysaccharide (PSA) produced by Aerococcus viridans. METHODS:A. viridans was incubated with human plasma and Hakata-depleted plasma to examine Hakata binding and growth inhibition of A. viridans through binding with PSA. RESULTS: When A. viridans was mixed with human acid citrate dextrose-one (ACD-A) plasma, it pulled down Hakata complexed with mannose-binding lectin (MBL)-associated serine proteases 1 and 2 (MASP-1 and MASP-2). This complex had the potential for C4 deposition. Serum Hakata circulates as Hakata-MASPs complex in the blood and is proteolytically active. By mixing A. viridans with human plasma, we prepared a Hakata-depleted plasma, deficient in Hakata-MASPs complex. This plasma failed to inhibit A. viridans growth plasma, but does not inhibit Staphylococcus aureus, Yersinia enterocolitica and Escherichia coli. However, a decrease of growth inhibition of A. viridans in Hakata-depleted plasma could be restored by adding a Hakata-MASPs complex preparation in a dose-dependent manner. On the other hand, the Hakata-MASPs complex exhibited strong binding to A. viridans, but not to S. aureus, Y. enterocolitica and E. coli. CONCLUSIONS: The serum concentration of Hakata is linked with growth inhibition of A. viridans upon binding of Hakata via PSA. Copyright 2002 Elsevier Science B.V.
Authors: Y Endo; N Nakazawa; Y Liu; D Iwaki; M Takahashi; T Fujita; M Nakata; M Matsushita Journal: Immunogenetics Date: 2005-11-22 Impact factor: 2.846
Authors: J M Ruskamp; M O Hoekstra; D S Postma; M Kerkhof; R W Bottema; G H Koppelman; M M Rovers; A H Wijga; J C de Jongste; B Brunekreef; E A M Sanders Journal: Clin Exp Immunol Date: 2009-03 Impact factor: 4.330
Authors: A P M Atkinson; M Cedzynski; J Szemraj; A St Swierzko; L Bak-Romaniszyn; M Banasik; K Zeman; M Matsushita; M L Turner; D C Kilpatrick Journal: Clin Exp Immunol Date: 2004-12 Impact factor: 4.330
Authors: László József Barkai; Emese Sipter; Dorottya Csuka; Zoltán Prohászka; Katrine Pilely; Peter Garred; Nóra Hosszúfalusi Journal: Front Immunol Date: 2019-03-20 Impact factor: 7.561